Ram F S F, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes N C
Massey University - Albany, School of Health Sciences, Private Bag 102 904, North Shore Mail Centre, Auckland, New Zealand.
Cochrane Database Syst Rev. 2006 Apr 19(2):CD004403. doi: 10.1002/14651858.CD004403.pub2.
Most patients with an exacerbation of chronic obstructive pulmonary disease (COPD) are treated with antibiotics. However the value of their use remains uncertain. Some controlled trials of antibiotics have shown benefit (Berry 1960; Pines 1972) while others have not (Elmes 1965b; Nicotra 1982).
To conduct a systematic review of the literature estimating the value of antibiotics in the management of acute COPD exacerbations.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2005); MEDLINE (1966 to December 2005); EMBASE (1974 to December 2005); Web of Science (December 2005), and other electronically available databases.
Randomised controlled trials (RCTs) in patients with acute COPD exacerbations comparing antibiotic (for a minimum of five days) and placebo.
Data were analysed using Review Manager software. Continuous data were analysed using weighted mean differences (WMD) and 95% confidence intervals (CI). Relative risks (RR) (and 95% CI) were calculated for all dichotomous data. Where appropriate, number needed to treat to benefit (NNT) and 95% CI were calculated.
Eleven trials with 917 patients were included. Ten trials used increased cough, sputum volume and purulence diagnostic criteria for COPD exacerbation. Eight-hundred and fifty-seven patients provided data for outcomes including mortality, treatment failure, increased sputum volume, sputum purulence, PaCO(2), PaO(2), peak flow and adverse events. Antibiotic therapy regardless of antibiotic choice significantly reduced mortality (RR 0.23; 95% CI 0.10 to 0.52 with NNT of 8; 95% CI 6 to 17), treatment failure (RR 0.47; 95% CI 0.36 to 0.62 with NNT of 3; 95% CI 3 to 5) and sputum purulence (RR 0.56; 95% CI 0.41 to 0.77 with NNT of 8; 95% CI 6 to 17). There was a small increase in risk of diarrhoea with antibiotics (RR 2.86; 95% CI 1.06 to 7.76). Antibiotics did not improve arterial blood gases and peak flow.
AUTHORS' CONCLUSIONS: This review shows that in COPD exacerbations with increased cough and sputum purulence antibiotics, regardless of choice, reduce the risk of short-term mortality by 77%, decrease the risk of treatment failure by 53% and the risk of sputum purulence by 44%; with a small increase in the risk of diarrhoea. These results should be interpreted with caution due to the differences in patient selection, antibiotic choice, small number of included trials and lack of control for interventions that influence outcome, such as use of systemic corticosteroids and ventilatory support. Nevertheless, this review supports antibiotics for patients with COPD exacerbations with increased cough and sputum purulence who are moderately or severely ill.
大多数慢性阻塞性肺疾病(COPD)急性加重期患者接受抗生素治疗。然而,抗生素使用的价值仍不确定。一些抗生素对照试验显示有益(贝里,1960年;派恩斯,1972年),而其他试验则未显示(埃尔姆斯,1965年b;尼科特拉,1982年)。
对文献进行系统评价,评估抗生素在急性COPD加重期治疗中的价值。
我们检索了Cochrane对照试验中心注册库(CENTRAL)(《Cochrane图书馆》2005年第4期);MEDLINE(1966年至2005年12月);EMBASE(1974年至2005年12月);科学引文索引(2005年12月),以及其他电子可用数据库。
急性COPD加重期患者的随机对照试验(RCT),比较抗生素(至少使用五天)与安慰剂。
使用Review Manager软件进行数据分析。连续数据采用加权均数差(WMD)和95%置信区间(CI)进行分析。对所有二分数据计算相对危险度(RR)(及95%CI)。在适当情况下,计算获益所需治疗人数(NNT)及95%CI。
纳入11项试验,共917例患者。10项试验采用咳嗽加重、痰液量增加和痰液脓性作为COPD加重的诊断标准。857例患者提供了包括死亡率、治疗失败、痰液量增加、痰液脓性、动脉血二氧化碳分压(PaCO₂)、动脉血氧分压(PaO₂)、峰值呼气流速及不良事件等结局的数据。无论选择何种抗生素,抗生素治疗均显著降低死亡率(RR 0.23;95%CI 0.10至0.52,NNT为8;95%CI 6至17)、治疗失败率(RR 0.47;95%CI 0.36至0.62,NNT为3;95%CI 3至5)和痰液脓性(RR 0.56;95%CI 0.41至0.77,NNT为8;95%CI 6至17)。使用抗生素会使腹泻风险略有增加(RR 2.86;95%CI 1.06至7.76)。抗生素并未改善动脉血气和峰值呼气流速。
本综述表明,在咳嗽加重且痰液脓性增加的COPD加重期,无论选择何种抗生素,均可使短期死亡风险降低77%,治疗失败风险降低53%,痰液脓性风险降低44%;腹泻风险略有增加。由于患者选择、抗生素选择、纳入试验数量较少以及缺乏对影响结局的干预措施(如全身使用糖皮质激素和通气支持)的控制等方面存在差异,这些结果应谨慎解读。尽管如此,本综述支持对中度或重度病情、咳嗽加重且痰液脓性增加的COPD加重期患者使用抗生素。